Monitoring Cyclosporine of Pre-dose and Post-dose Samples Using Nonextraction Homogeneous Immunoassay

Therapeutic Drug Monitoring

Volumn 26, Issue 1, 2004, Pages 58-67

  Loor, Rueyming ^a   Pope, Lisa ^a   Boyd, Rose ^a   Wood, Kristopher ^a   Bodepudi, Vani ^a  

^a Microgenics Corporation   (United States)

Author keywords

CEDIA cyclosporine assay; Cyclosporine

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; DILUTION; DRUG MONITORING; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; NONEXTRACTION HOMOGENEOUS IMMUNOASSAY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION;

CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSIVE AGENTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0942287048     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200402000-00013     Document Type: Article

References (34)

1. Borel JF. Cyclosporin A-present experimental status, Transplant Proc, 1981;13:344-348.
2. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science. 1991;251:283-287,
3. Chaudhuri B, Stephan C. Only in the presence of immunophilins can cyclosporin and FK506 disrupt binding of calcineurin A to its autoinhibitory domain yet strengthen interaction between calcineurin A and B subunits. Biochem Biophys Res Commun. 1995;215:781-790.
4. Britton S, Palacios R. Cyclosporin A usefulness, risks and mechanism of action, Immunol Rev. 1982;65:5-22,
5. Keown PA, Essery GL, Stiller CR, et al. Mechanisms of immunosuppression by cyclosporin. Transplant Proc. 1981;13:386-389.
6. Sells RA. A prospective randomized substitutive trial of cyclosporine as a prophylactic agent in human renal transplant rejection. Transplant Proc. 1983;15:2495-2500.
7. Shaw LM, Kaplan B, Kaufman D. Toxic effects of immunosuppressive drugs: mechanism and strategies for controlling them. Clin Chem. 1996; 42:1316-1320.
8. Barton CH, Vaziri ND. Cyclosporine nephrotoxicity. Int J ArtifOrgans. 1985;8:291-296.
9. Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephrotoxicity. N Engl J Med. 1984;311:699-705.
10. Atkinson K, Biggs J, Dodds A, et al. Cyclosporine-associated hepatotoxicity after allogeneic marrow transplantation in man: differentiation from other cause of posttransplant liver disease. Transplant Proc. 1983; 15: 2761.
11. Hows JM, Chipping PM, Fairhead S, et al. Nephrotoxicity in bone marrow transplant recipients treated with cyclosporine A. Br J Hematol. 1983;54: 69-78.
12. Rosano TG, Freed BM, Pell MA, et al. Cyclosporine metabolites in human blood and renal tissue. Transplant Proc. 1986;18(Suppl 5):35-40.
13. Kahan BD, Ried M, Newburger J. Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc. 1983;15:446-453.
14. Shaw LM, Bowers L, Demers L, et al. Critical issues in cyclosporine monitoring: report of the task force on cyclosporine. Clin Chem. 1987;33: 1269-1288.
15. Van Buren D, Wideman CA, Reid M, et al. The antagonistic effect of rifampin upon cyclosporine bioavailability. Transplant Proc. 1984;16: 1642-1645.
16. Freeman DJ, Lanpacis A, Keown PA, et al. Evaluation of cyclosporine-phenytoin interaction with observations on cyclosporine metabolites. Br J Clin Pharmacol. 1984;18:887-893.
17. Oellerich M, Armstrong VW, Kahan B, et al. Lake Louise consensus conference on cyclosporin monitoring in organ transplantation: Report of the consensus panel. Ther Drug Monit. 1995;17:642-654.
18. Morris RG, Russ GR, Cervieeli MJ, et al. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin Neoral® at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit. 2002;24:479-486.
19. Andrews DJ, Cramb R. Cyclosporin: revisions in monitoring guidelines and review of current analytic methods. Ann Clin Biochem. 2002;39:424-435.
20. Mahalati K, Belitsky P, Sketris I. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation. 1999; 68:55-62.
21. Cole E, Keown P, Landsberg D, et al. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal recipients: a report of the Canadian Neoral renal study group. Transplantation. 1998;65:505-510.
22. max) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8). Transplantation. 1999;67:1133-1137.
23. Levy G, Burra P, Cavallari A, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation. 2002;73:953-959.
24. Schutz E, Streit F, Dias V, et al. Immunoassays in comparison to LC-MS/MS, is there a difference between trough (C0) and C2 levels? Ther Drug Monit. 2001;23:471.
25. David-Neto E, Araujo L, Brito Z, et al. Sampling strategy to calculate the cyclosporine-A area under the time-concentration curve. Am J Transplant. 2002;2:545-550.
26. Holt D, Armstrong V, Griesmacher A, et al. International Federation of Clinical Chemistry Association of Therapeutic Drug Monitoring and Clinical Toxicology Working Group in Immunosuppressive Drug Monitoring. Ther Drug Monit. 2002;24:59-67.
27. Henderson D, Friedman SB, Harris JD, et al. CEDIA, a new homogeneous immunoassay system. Clin Chem. 1986;32:1637-1641.
28. CEDIA© Cyclosporine Plus Assay. Product insert. Fremont, CA: Microgenics Corp, 2003.
29. Taylor PJ, Salm P, Lynch SV, et al. Simultaneous quantitation of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2002;22:608-612.
30. Schutz E, Svinarov D, Shipkova M, et al. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and EMIT): a critical overview of performance characteristics and comparison with HPLC. Clin Chem. 1998;44: 2158-2164.
31. Khoschsorur G, Semmelrock HJ, Rodl S, et al. Rapid, sensitive high-performance liquid chromatographic method for the determination of cyclosporine A and its metabolites M1, M17, and M21. Chromatogr. 1997; 690:367-372.
32. Streit F, Armstrong VW, Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A in whole blood. Clin Chem. 2002;48:955-958.
33. Tamolang MB, Liu WT, Pang H, et al. A rifampicin-induced hepatic microsomal enzyme system for the generation of cyclosporine metabolites. Pharm Res. 1995;32:141-148.
34. Kelly PA, Wang H, Napoli KL, et al. Metabolism of cyclosporine by cytochrome P450 3A9 and 3A4. Eur J Drug Metab Pharmacokinet. 1999; 24:321-328.